Subscribe To

Price Alert Latest News Economic Calendar News

UPTD / Estrella Immunopharma Nears Completion Of SPAC Listing

Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China's UP Fintech. The cancer therapy developer was only founded last year but thinks it can start generating revenue as soon as 2025 using proprietary technology from its founder. Its lack of revenue and unclear future prospects, combined with uncertainties related to its China ties, mean its stock could quickly come under pressure if and when it finally completes its SPAC listing. Read More

Demo Live Account See Partner Details

Content Topics

Estrella

Immunopharma

Nears

Completion

Spac

Listing

Stock

UPTD

Posted: Sep 19 2023, 01:30

Author Name: Seeking Alpha

UPTD News

By Seeking Alpha
September 19, 2023

Estrella Immunopharma Nears Completion Of SPAC Listing

Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China's UP Fintech. The cancer therapy developer was only f

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.